{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:30:49Z","timestamp":1786735849319,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijc.ijc_506_18","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T03:14:45Z","timestamp":1570763685000},"page":"354","source":"Crossref","is-referenced-by-count":8,"title":["Atypical chronic myeloid leukemia achieving good response with azacitidine"],"prefix":"10.4103","volume":"56","author":[{"given":"Atsushi","family":"Marumo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Tanosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.268960-1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia.Proposals by the French-American-British Cooperative Leukaemia Group","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0019-509X.268960-2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","article-title":"Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia","author":"Tong","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0019-509X.268960-3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1078155215605662","article-title":"Activity of single-agent decitabine in atypical chronic myeloid leukemia","author":"Hausmann","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"key-10.4103\/0019-509X.268960-4","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.268960-5","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.268960-6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: A Retrospective study from the chronic malignancies Working Party of the European Society for Blood and Marrow Transplantation","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0019-509X.268960-7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","author":"Maxon","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.268960-8","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","author":"Fleischman","year":"2013","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.268960-9","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.3324\/haematol.2017.163790","article-title":"Ruxolitinib, a potent JAK1\/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia","author":"Gunawan","year":"2017","journal-title":"Haematologica"},{"key":"key-10.4103\/0019-509X.268960-10","first-page":"e414","article-title":"Durable disease control with MEK inhibition in a patient with NRAS-mutated atypical chronic myeloid leukemia","author":"Khanna","year":"2015","journal-title":"Cureus"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:18Z","timestamp":1786732458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_506_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"alternative-id":["268960"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_506_18","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}